Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001835268-24-000023
Filing Date
2024-09-05
Accepted
2024-09-05 16:20:33
Documents
102
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 6-K cntb-20240630.htm   iXBRL 6-K 951254
2 EX-99.1 cntbh12024earningsreleasef.htm EX-99.1 62593
  Complete submission text file 0001835268-24-000023.txt   6092553

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cntb-20240630.xsd EX-101.SCH 74335
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cntb-20240630_cal.xml EX-101.CAL 90573
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cntb-20240630_def.xml EX-101.DEF 180418
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cntb-20240630_lab.xml EX-101.LAB 546698
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cntb-20240630_pre.xml EX-101.PRE 391655
104 EXTRACTED XBRL INSTANCE DOCUMENT cntb-20240630_htm.xml XML 977121
Mailing Address 12265 EL CAMINO REAL, SUITE 350 SAN DIEGO CA 92130
Business Address 12265 EL CAMINO REAL, SUITE 350 SAN DIEGO CA 92130 858-727-1040
Connect Biopharma Holdings Ltd (Filer) CIK: 0001835268 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-40212 | Film No.: 241281654
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)